J De Castro1, J L González-Larriba2, S Vázquez3, B Massutí4, J M Sanchez-Torres5, M Dómine6, P Garrido7, A Calles8, A Artal9, R Collado10, R García11, M Sereno12, M Majem13, J A Macías14, O Juan15, J Gómez-Codina16, B Hernández17, M Lázaro18, A L Ortega19, M Cobo20, J M Trigo21, E Carcereny22, C Rolfo23, S Macia24, J Muñoz25, P Diz26, M Méndez27, F Rosillo28, L Paz-Ares29, J V Cardona30, D Isla31. 1. Medical Oncology Unit--Department of Translational Oncology, Hospital Universitario La Paz-IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain. javier.decastro@salud.madrid.org. 2. Hospital Clínico Universitario San Carlos, Madrid, Spain. 3. Hospital Universitario Lucus Augusti, Lugo, Spain. 4. Hospital General Universitario de Alicante, Alicante, Spain. 5. MD Anderson Cancer Center Madrid, Madrid, Spain. 6. Fundación Jiménez Díaz, Madrid, Spain. 7. Hospital Ramón y Cajal, Madrid, Spain. 8. Centro Integral Oncológico Clara Campal, Madrid, Spain. 9. Hospital Universitario Miguel Servet, Saragossa, Spain. 10. Hospital San Pedro de Alcántara, Cáceres, Spain. 11. Hospital Universitario Gregorio Marañón, Madrid, Spain. 12. Hospital Infanta Sofía, Madrid, Spain. 13. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 14. Hospital General Universitario Morales Meseguer, Murcia, Spain. 15. Hospital Arnau Vilanova, Valencia, Spain. 16. Hospital La Fe, Valencia, Spain. 17. Complejo Hospitalario de Navarra--Hospital de Navarra, Pamplona, Spain. 18. Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain. 19. Complejo Hospitalario de Jaén, Jaén, Spain. 20. Hospital Regional Universitario Carlos Haya, Málaga, Spain. 21. Hospital Universitario Virgen de la Victoria, Málaga, Spain. 22. Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. 23. University Hospital of Antwerp, Antwerp, Belgium. 24. Hospital General Universitario de Elda, Alicante, Spain. 25. Hospital Universitario Doctor Peset, Valencia, Spain. 26. Complejo Asistencial Universitario de León, León, Spain. 27. Hospital Universitario de Móstoles, Madrid, Spain. 28. Complejo Hospitalario Torrecárdenas, Almería, Spain. 29. Hospital Universitario Virgen del Rocío, Seville, Spain. 30. Roche Farma, S.A., Madrid, Spain. 31. Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain.
Abstract
BACKGROUND/AIM: First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. PATIENTS AND METHODS: This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. RESULTS: Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. CONCLUSION: Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
BACKGROUND/AIM: First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. PATIENTS AND METHODS: This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. RESULTS: Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. CONCLUSION: Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
Authors: Matthias Preusser; David Capper; Aysegül Ilhan-Mutlu; Anna Sophie Berghoff; Peter Birner; Rupert Bartsch; Christine Marosi; Christoph Zielinski; Minesh P Mehta; Frank Winkler; Wolfgang Wick; Andreas von Deimling Journal: Acta Neuropathol Date: 2012-01-03 Impact factor: 17.088
Authors: Ariel Lopez-Chavez; Todd Young; Sophie Fages; Larry Leon; Joan H Schiller; Afshin Dowlati; Julie R Brahmer; David H Johnson; Alan Sandler Journal: J Thorac Oncol Date: 2012-11 Impact factor: 15.609
Authors: Fabrice Barlesi; Arnaud Scherpereel; Achim Rittmeyer; Antonio Pazzola; Neus Ferrer Tur; Joo-Hang Kim; Myung-Ju Ahn; Joachim G J V Aerts; Vera Gorbunova; Anders Vikström; Elaine K Wong; Pablo Perez-Moreno; Lada Mitchell; Harry J M Groen Journal: J Clin Oncol Date: 2013-07-08 Impact factor: 44.544
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544